These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31256280)

  • 41. Bright tongue sign in Pompe disease.
    Karam C
    Neurology; 2016 Jan; 86(4):401. PubMed ID: 26810423
    [No Abstract]   [Full Text] [Related]  

  • 42. Targeted population screening of late onset Pompe disease in unspecified myopathy patients for Korean population.
    Lee JH; Shin JH; Park HJ; Kim SZ; Jeon YM; Kim HK; Kim DS; Choi YC
    Neuromuscul Disord; 2017 Jun; 27(6):550-556. PubMed ID: 28433475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A database for screening and registering late onset Pompe disease in Turkey.
    Gokyigit MC; Ekmekci H; Durmus H; Karlı N; Koseoglu E; Aysal F; Kotan D; Ali A; Koytak PK; Karasoy H; Yaman A; Sengun İS; Sayin R; Tiftikcioglu BI; Soysal A; Tutkavul K; Bayrak AO; Kısabay A; Elci MA; Yayla V; Yılmaz İA; Ozdamar SE; Erdogan C; Tasdemir N; Serdaroglu Oflazer P;
    Neuromuscul Disord; 2018 Mar; 28(3):262-267. PubMed ID: 29395671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for late-onset Pompe disease in western Denmark.
    Hansen JS; Pedersen EG; Gaist D; Bach FW; Vilholm OJ; Sandal B; Weitemeyer L; Nielsen K; Schlesinger FE; Preisler N; Vissing J; Andersen H
    Acta Neurol Scand; 2018 Jan; 137(1):85-90. PubMed ID: 28832912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
    Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
    J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BNIP3 Is Involved in Muscle Fiber Atrophy in Late-Onset Pompe Disease Patients.
    Carrasco-Rozas A; Fernández-Simón E; Suárez-Calvet X; Piñol-Jurado P; Alonso-Pérez J; de Luna N; Schoser B; Meinke P; Domínguez-González C; Hernández-Laín A; Paradas C; Rivas E; Illa I; Olivé M; Gallardo E; Díaz-Manera J
    Am J Pathol; 2022 Aug; 192(8):1151-1166. PubMed ID: 35605642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffusion tensor imaging reveals changes in non-fat infiltrated muscles in late onset Pompe disease.
    Rehmann R; Froeling M; Rohm M; Forsting J; Kley RA; Schmidt-Wilcke T; Karabul N; Meyer-Frießem CH; Vollert J; Tegenthoff M; Vorgerd M; Schlaffke L
    Muscle Nerve; 2020 Oct; 62(4):541-549. PubMed ID: 32654203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diaphragmatic dysfunction in neuromuscular disease, an MRI study.
    Harlaar L; Ciet P; van Tulder G; Brusse E; Timmermans RGM; Janssen WGM; de Bruijne M; van der Ploeg AT; Tiddens HAWM; van Doorn PA; van der Beek NAME
    Neuromuscul Disord; 2022 Jan; 32(1):15-24. PubMed ID: 34973872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adapted physical activity and therapeutic exercise in late-onset Pompe disease (LOPD): a two-step rehabilitative approach.
    Iolascon G; Vitacca M; Carraro E; Chisari C; Fiore P; Messina S; Mongini T; Moretti A; Sansone VA; Toscano A; Siciliano G;
    Neurol Sci; 2020 Apr; 41(4):859-868. PubMed ID: 31811531
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Restrictive Arteriopathy in Late-Onset Pompe Disease: Case Report and Review of the Literature.
    Malhotra K; Carrington DC; Liebeskind DS
    J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):e172-e175. PubMed ID: 28647415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence.
    Iolascon G; Vitacca M; Carraro E; Chisari C; Fiore P; Messina S; Mongini TEG; Sansone VA; Toscano A; Siciliano G
    Acta Myol; 2018 Dec; 37(4):241-251. PubMed ID: 30944902
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Altered activation of the diaphragm in late-onset Pompe disease.
    Smith BK; Corti M; Martin AD; Fuller DD; Byrne BJ
    Respir Physiol Neurobiol; 2016 Feb; 222():11-5. PubMed ID: 26612101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression from respiratory dysfunction to failure in late-onset Pompe disease.
    Berger KI; Chan Y; Rom WN; Oppenheimer BW; Goldring RM
    Neuromuscul Disord; 2016 Aug; 26(8):481-9. PubMed ID: 27297666
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
    Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
    Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inspiratory Muscle Training in Late-Onset Pompe Disease: The Effects on Pulmonary Function Tests, Quality of Life, and Sleep Quality.
    Aslan GK; Huseyinsinoglu BE; Oflazer P; Gurses N; Kiyan E
    Lung; 2016 Aug; 194(4):555-61. PubMed ID: 27106274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.
    Sheng B; Chu YP; Wong WT; Yau EKC; Chen SPL; Luk WH
    BMC Res Notes; 2017 Jul; 10(1):351. PubMed ID: 28754168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Follow-up analysis of voice quality in patients with late-onset Pompe disease.
    Szklanny K; Tylki-Szymańska A
    Orphanet J Rare Dis; 2018 Oct; 13(1):189. PubMed ID: 30367637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Model-Informed Approach Supporting Approval of Nexviazyme (Avalglucosidase Alfa-ngpt) in Pediatric Patients with Late-Onset Pompe Disease.
    Li RJ; Ma L; Drozda K; Wang J; Punnoose AR; Jeng LJB; Maynard JW; Zhu H; Pacanowski M
    AAPS J; 2023 Jan; 25(1):16. PubMed ID: 36653728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinants and Characterization of Locomotion in Adults with Late-Onset Pompe Disease: New Clinical Biomarkers.
    Maulet T; Cattagni T; Dubois F; Roche N; Laforet P; Bonnyaud C
    J Neuromuscul Dis; 2023; 10(5):963-976. PubMed ID: 37545258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.